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The vertebrate immune system exists in equilibrium with the microbial world. The innate
immune system recognizes pathogen-associated molecular patterns via a family ofToll-like
receptors (TLR) that activate cells upon detection of potential pathogens. Because some
microbes beneﬁt their hosts, mobilizing the appropriate response, and then controlling that
response is critical in the maintenance of health.TLR4 recognizes the various forms of lipid
A produced by Gram-negative bacteria. Depending on the structural form of the eliciting
lipid A molecule, TLR4 responses range from a highly inﬂammatory endotoxic response
involving inﬂammasome and other pro-inﬂammatory mediators, to an inhibitory, protective
response. Mounting the correct response against an offending microbe is key to maintain-
ing health when exposed to various bacterial species. Further study of lipid A variants may
pave the way to understanding how TLR4 responses are generally able to avoid chronic
inﬂammatory damage.
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INTRODUCTION
The innate immune response results from a highly regulated set
of reactions that initiates and orchestrates the entire response to
infection, injury, and tumorogenesis (Starczynowski and Karsan,
2010; Arslan et al., 2011; Osawa et al., 2011; Rock et al., 2011).
However, dysregulation of the innate immune response leads to
poor homeostasis that can initiate pathologic conditions includ-
ing arthritis, autoimmunity, and cancer (Grivennikov et al., 2010;
Bettini and Vignali, 2011; Delogu et al., 2011; Sikora and Grom,
2011; Davalos and Akassoglou, 2012).
Inﬂammasomes are intracellular staging areas organized to
allow maturation of the powerful inﬂammatory cytokines inter-
leukin (IL-) 1β, IL-18, and IL-33 from inactive precursors (Arend
et al., 2008; Dunne, 2011). These cytokines are produced early
upon exposure to infectious agents, often triggering receptors spe-
ciﬁc for chemistries conserved in microbial life (Janeway and
Medzhitov, 2002; Kawai and Akira, 2009). The inﬂammatory
environment produced by inﬂammasomes is important for the
clearance of offendingmicrobes, a process that involves the induc-
tion of other inﬂammatory cytokines (TNFα, IL-1β, and IL-6),
chemokines (Schilling et al., 2002), and other factors that lead to
the activation and differentiation of adaptive immune cells (Foell
et al., 2007; Blanco et al., 2008). Dysregulation or over-activation
of these cytokines can lead tomassive inﬂammatory states so acute
that they result in the death of the host after sterile clearance of
infection.
Toll-like receptors (TLR) are innate immune cell receptors
that recognize various conserved pathogen-associated molecular
patterns (PAMP) and host-derived damage-activated molecular
patterns (DAMP; Janeway and Medzhitov, 2002; Foell et al., 2007;
Kawai and Akira, 2009). There are at least 13 distinct mammalian
TLR that function as either homo- or hetero-dimers (Roach
et al., 2005). TLR4 requires MD2 to bind its canonical ligand,
lipopolysaccharide (LPS; Poltorak et al., 1998; Kennedy et al.,
2004). LPS is a major cell wall component of all Gram-negative
bacteria; however, its molecular structure differs depending on the
bacterial species. In general, LPS molecules are made up of an O-
antigen of varying lengths, the polysaccharide core, and the lipid
A moiety (Raetz and Whitﬁeld, 2002). The lipid A region is the
endotoxin component of the molecule, and is the portion of the
molecule that binds TLR4/MD2 (Carpenter and O’Neill, 2009).
Variations in the structure of lipid A determine inﬂammatory
and immunostimulatory effects of TLR4 binding. The lipid A
structure consists of a phosphorylated diglucosamine head group
with a number of fatty acid side chains. The fatty acid (acyl)
side chains are bound within the MD2 co-receptor via a large
hydrophobic pocket, and the resultant complex then associates
with a TLR4 monomer (Park et al., 2009). In addition, the lipid A
diglucosamine head group, through phosphorylation of its 1- and
4′ carbons, associates with both TLR4 molecules in the signaling-
competent dimer (Park et al., 2009). Structure-function studies of
lipid A or structural mimetics demonstrate that differences in the
number and the length of the acyl chain side groups are impor-
tant in signaling strength of TLR4 (Coats et al., 2003; Stover et al.,
2004; Reife et al., 2006). For example, Stover et al. (2004) showed
that there is an optimal acyl chain length for TLR4 recognition of
synthetic hexa-acyl lipid A mimetics. Analysis of the crystal struc-
ture of the ecto-domain of TLR4-associated with MD2 and lipid
A suggests there is critical numbers or arrangement of the acyl
chains of lipid A that are required both to bind within the MD2
pocket and associate with the monomer TLR4 molecule (Park
et al., 2009).
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The phosphorylation state of lipid A also affects its function
through changes in the ability to engage TLR4. The prototypic
lipid A structure is di-phosphorylated, with a phosphate on each
of the glucosamine moieties. Unphosphorylated lipid A does not
signal through TLR4, and thus acts as an inhibitor of lipid A
(Coats et al., 2011). Monophosphoryl lipid A (MPLA) from Sal-
monella minnesota rough mutant Re 595 has been shown to be
0.1–1% as toxic (Ribi, 1984; Baldrick et al., 2002), but nearly as
immunostimulatory as its parental LPS form (Thompson et al.,
2005; Mata-Haro et al., 2007; Didierlaurent et al., 2009). The loss
of a single phosphate froma synthetic formof lipidAalsodecreases
the production of pro-inﬂammatory cytokines (Cekic et al., 2009).
Recently, MPLA has been approved by the USDA as MPL® adju-
vant as the ﬁrst TLR agonist to be approved for use as a vaccine
adjuvant based on its ability to direct adaptive immune responses
with little toxicity (Didierlaurent et al., 2009).
Chronic inﬂammation can lead to serious conditions, including
atherosclerosis, arthritis, and cancer (Coussens and Werb, 2002;
Duewell et al., 2010).VariousGram-negative bacteria infect chron-
ically and are associated with inﬂammatory disease and cancer.
Chronic Helicobacter pylori infection causes peptic ulcers which
are associated with stomach cancer (Suerbaum and Michetti,
2002). Lyme disease-associated arthritis occurs in individuals
chronically infected with the Gram-negative spirochete, Borrelia
burgdorferi (Murray and Shapiro, 2010). Chronic inﬂammation
due to improper or lack of control over inﬂammasome function
has also been linked to a variety of immune system disorders,
including various forms of arthritis as well as Crohn’s disease and
ulcerative colitis.
In this Review, we will discuss the role of TLR4 on inﬂam-
masome activation, with a focus on the NLRP3 form of the
inﬂammasome. In addition, the phenomenon of decreased TLR4
inﬂammatory signals when the lipidA agonist structure is changed
in various ways will be addressed.
NLRP3 INFLAMMASOME ACTIVATION
Inﬂammasomes are multi protein structures formed in the cyto-
plasm of activated innate immune cells that lead to thematuration
of IL-1β and IL-18 from inactive pro-proteins to their active,
mature forms. The NLRP3 [nucleotide-binding oligomerization
domain (NOD)-like receptor family, pryin domain containing 3]-
inﬂammasome is most often associated with TLR4 activation. The
other proteins of the NLRP3 inﬂammasome are ASC (apoptosis-
associated speck-like protein containing a CARD domain), the
pro-inﬂammatory caspase, caspase-1, and the precursor forms
of IL-1β or IL-18 or both (Martinon et al., 2002; Schroder and
Tschopp, 2010).
Two distinct signals are required for the production and secre-
tion of mature IL-1β or IL-18 via the NLRP3 inﬂammasome
(Figure 1). First, a priming signal occurs either through TLR4 or
IL-1 receptor. Priming leads to transcription and translation of the
inactive pro-forms of IL-1β or IL-18. We and others have shown
that an increase in NLRP3 protein abundance occurs during this
priming step, and that this increase plays a key role in the ultimate
maturation of IL-1β (Bauernfeind et al., 2009; Embry et al., 2011).
Priming alone does not lead to secretion of mature IL-1β because
primed cells simply harbor immature pro-IL-1β; an activation
signal that leads to inﬂammasome assembly and the proteolytic
activity of caspase-1 is also needed. Known activation signals
include extracellular ATP, taken up through the P2X7 puriner-
gic receptor (Pelegrin et al., 2008), and phagocytosed crystalline
(Martinon et al., 2006) or particulate structures that lyse phago-
cytic vesicles via a cathepsinB-dependentmechanism(Niemi et al.,
2011). After the activation signals, NLRP3 acts as the scaffold-
ing protein that allows the spontaneous assembly of the accessory
inﬂammasome components. In the presence of other inﬂamma-
some components, expressionof NLRP3 leads to the productionof
one very large inﬂammasomeor“speck”cluster per cell (Stutz et al.,
2009); single specks are visible in primed/activated cells within
5 h (Embry et al., 2011). The assembled inﬂammasome includes
enzymatically active caspase-1 that cleaves the precursor form of
IL-1β, which can lead to secretion of both the cytokine and active
caspase-1 from the cells (Figure 1a). Tight regulation of pro-IL-1β
maturation and related pro-inﬂammatory proteins underscores
the importance of avoiding potential damage to healthy tissue.
This regulation is evidenced by the observation that two distinct
steps are required to generate and secrete the active forms cytokine
suggesting several different levels at which therapeutics may be
applied to prevent or control inﬂammation.
NLRP3 MUTATIONS LEAD TO AUTO-INFLAMMATORY
DISEASES
In humans as well as in mouse models, gain-of-function poly-
morphisms, or mutations in the gene encoding NLRP3 are asso-
ciated with several similar inﬂammatory conditions that are
episodic in nature, occurring in ﬂares after periods of non-activity.
These conditions include familial cold auto-inﬂammatory syn-
drome, Muckle–Wells syndrome, cryopyrin-associated periodic
syndromes (CAPS), andneonatal onsetmultisystem inﬂammatory
disease (NOMID; Akazawa et al., 2004; Koike et al., 2007; Kubota
and Koike, 2010). Chronic inﬂammatory conditions are associ-
ated with an increased risk for development of colorectal cancer
and inﬂammatory bowel diseases, such as ulcerative colitis, and
Crohn’s disease (McDermott and Aksentijevich, 2002). The auto-
inﬂammatory episodes typical of these conditions make sense
in the framework of inﬂammasome formation and regulation.
Even if NLRP3 is expressed at inappropriate levels, other prim-
ing signals are required for the expression of pro-inﬂammatory
cytokines. Therefore, therapeutic potential lies in gaining con-
trol of the NLRP3 inﬂammasome priming factors and inhibitory
signals, or both.
Although increased function of NLRP3 is associated with
increased inﬂammation, deletion mutants of NLRP3 do not result
in the opposite phenotype. In mice, single deletion mutants of
NLRP3 inﬂammasome components NLRP3, caspase-1, or ASC,
are also more susceptible to both dextran sulfate sodium (DSS)-
induced colitis and inﬂammation-associated colon cancer. How-
ever, NLRP3 deﬁcient mice have a less pronounced association
with cancer development than caspase-1 deﬁcient mice. Further
studies are required to determine if the difference is related to
a regulatory function of the NLRP3 inﬂammasome in control-
ling cancer development caused by chronic inﬂammation or if it
is possibly due to a decrease in apoptosis via reduced caspase-1
activity (Allen et al., 2010). Another study that found increased
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FIGURE 1 | Increased NLRP3 expression via MyD88 leads to
inflammasome formation and processing of IL-1β after lipid A treatment.
Priming (1–3) and activation (4–7) are required for mature IL-1β secretion. (1)
TLR4/MD2 binds lipid A forming endotoxin receptor dimers that signal
through either MyD88 or TRIF, or both (2) to activate NF-κB. The
MyD88-dependent “early” phase of NF-κB activity results in increased
transcription of both nlrp3 and il1b genes. TRIF-dependent TLR4 signaling
occurs after receptor-mediated endocytosis of TLR4 leading to the “late”
phase of NF-κB activity, and increases il1b gene expression, but not nlrp3.
Inﬂammasome activation occurs in response to such agonists as extracellular
ATP which is sensed by the P2X7R and leads to K+ loss through the
pannexin-1 ion channel (4). If TLR4 signaling increases NLRP3 protein levels
(5a), such as with MyD88-competent LPS or DPLA, then the activation event
permits the newly expressed NLRP3 to aggregate with soluble ASC protein
and pro-caspase-1, leading to caspase-1 processing to its active form and
inﬂammasome assembly (6a). Pro-IL-1β that is associated with the
inﬂammasome is processed to mature IL-1β and secreted into the
extracellular space (7a). However, whenTLR4 priming does not adequately
increase NLRP3 expression (5b), as is the case with MPLA treatment, then
there is little to no NLRP3 protein to direct inﬂammasome assembly,
pro-caspase-1 does not get efﬁciently activated (6b), and any IL-1β that is
secreted is generally in the inactive pro-IL-1β form (7b).
DSS-induced colitis in NLRP3 deﬁcient mice showed poor regula-
tion of intestinal homeostasis, including decreases in IL-10 levels,
changes in the composition of intestinalmicrobiota, and decreases
of β-defensin production (Hirota et al., 2011). Changes in gut
microbiota inNLRP3deﬁcientmice include the presence of poten-
tially pathogenic Enterobacteriaceae genera. Similar changes in the
Enterobacteriaceae genera in the gutmicrobiota, including Proteus
species, occur in the TRUC (T-bet−/−Rag1−/− ulcerative colitis)
mouse model of spontaneous inﬂammatory bowel disease (Gar-
rett et al., 2010). These studies suggest a complex role forNLRP3 in
the control of local inﬂammation, such as in the intestine. There-
fore, the role of the NLRP3 inﬂammasome in determining the
composition of a healthy gut microbiota needs to be determined
before NLRP3 should be used as a therapeutic target to control
of chronic inﬂammation that leads to colon cancers. A selective
inhibitor of NLRP3 pro-inﬂammatory effects could be useful if
capable of suppressing only the pro-inﬂammatory effects without
affecting its beneﬁcial roles, such as controlling the homeostasis of
healthy microbiota.
MyD88-DEPENDENT SIGNALING IS REQUIRED TO PRIME
THE NLRP3 INFLAMMASOME DOWNSTREAM OF TLR4 AND
LIPID A
Preparations of MPLA from the Re595 rough mutant of S. min-
nesota have been shown to possess much lower toxicity than
parental, di-phosphorylated lipid A preparations (Ribi, 1984;
Thompson et al., 2005). In vivo, MPLA decreases inﬂammatory
signaling from TLR4 with minimal impairment of its immunos-
timulatory adjuvant effect on the initial clonal expansion of T cell
(Thompson et al., 2005; Mata-Haro et al., 2007). MPLA exerted
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effective immunostimulatory effects at this stage of the T cell
response since it retained to a signiﬁcant amount of TLR4 TRIF-
dependent signaling. In contrast, the TLR4 MyD88-dependent
pro-inﬂammatory signaling was markedly reduced, but not com-
pletely absent (Mata-Haro et al., 2007). This, “TRIF-biased” sig-
naling proﬁle obtained with MPLA has been modeled in vitro
using dendritic cell cultures and synthetic versions of the E. coli
form of monophosphoryl lipid A (sMPLA) or diphosphoryl lipid
A (sDPLA; Cekic et al., 2009, 2011). These molecules represent
the detoxiﬁed or the toxic versions of lipid A, respectively. Fol-
lowing the work of Okemoto et al. (2006) showing decreased
IL-1β production in response to MPLA, we hypothesized that
the difference in toxicity would at least partially be caused by
the reduced maturation of IL-1β using a TLR4 agonist that is
“poor” in MyD88-dependent signaling. However, in our cultured
dendritic cell system, both MyD88 and TRIF-signaling mutants
increased the Il1b mRNA abundance to a similar extent when
exposed to sDPLA. When using sDPLA or sMPLA to prime den-
dritic cell cultures with subsequent ATP activation, IL-1β pro-
tein levels were signiﬁcantly higher after sDPLA treatment as
compared to sMPLA treatment. Through Western Blot analy-
sis of the culture supernatants, we showed that the IL-1β that
was secreted after sMPLA treatment was actually the inactive,
pro-IL-1β rather than mature IL-1β present in the supernatants
from sDPLA-treated dendritic cells. We assessed the TLR4 sig-
naling requirements for these priming effects and determined
that although both TRIF and MyD88 adaptors contributed to the
increase in IL-1β transcription,MyD88-signaling was required for
the maturation of IL-1β from its inactive pro-form to its cleaved
mature form (Embry et al., 2011). The MyD88-dependent com-
ponent was then determined to be, at least in part, due to an
increase in transcription and production of NLRP3 during prim-
ing (Figure 1a). Failure to generate sufﬁcient MyD88-dependent
signaling resulted in low expression of NLRP3, which limited the
formation of inﬂammasomes when the activation signal, ATP, was
provided (Figure 1b). Not only was decreased inﬂammasome for-
mation assessed by decreased mature IL-1β secretion in response
to ATP signals, we also observed a near absence of “specks”
(using antibody against ASC), representing the fully formed
NLRP3 inﬂammasome in confocal microscopy. In summary,
these observations indicated a failure of inﬂammasome assem-
bly in cells primed with sMPLA (decreased MyD88-signaling),
as compared to sDPLA (intact MyD88-signaling; Embry et al.,
2011).
The ability to activate innate immune system cells in a man-
ner that limits the pro-inﬂammatory products produced is a goal
for clinical treatment of inﬂammatory conditions. These results
suggest that MPLA may prove safe and effective to use as a
single-agent therapy for certain chronic inﬂammatory conditions.
Indeed, MPLA promotes endotoxin receptor “tolerance” in the
absence of inﬂammatory outcomes (Madonna et al., 1986; Cekic
et al., 2011). The role of IL-1β in perpetuating pro-inﬂammatory
reactions makes the control of its production and function a
promising target in controlling inﬂammation and diseases asso-
ciated with inﬂammatory states. Therefore, the ability to acti-
vate the immunostimulatory arm of TLR4 signaling without
increasing production of mature IL-1β could be beneﬁcial in
controlling chronic inﬂammation in certain situations, especially
where low-level infection is a suspected cause.
NATURALLY-OCCURRING DIFFERENCES IN LIPID A
STRUCTURE CORRELATE WITH MICROBIAL VIRULENCE
For some time, we have been intrigued by the bifurcation of the
TLR4 signaling system: why is it able to independently activate a
largely pro-inﬂammatory program of events (MyD88-dependent)
and a separate program that can be thought of as anti-viral and
co-stimulatory (TRIF-dependent). This partial separation of sig-
naling events has lead to speculation that responses to various
lipid A agonists of TLR4 may be regulated separately, possibly
through unique binding characteristics of different ligands. Natu-
rally occurring forms of lipid A possess structural variations that
elicit differential effects in vivo that are known to correlate with
clinical presentations and microbial pathogenesis. For example,
Jarvis and colleagues have shown that the structural heterogeneity
of lipid oligosaccharide (LOS) produced by various clinical isolates
of Neisseria correlates with their abilities to induce TNFα produc-
tion bymonocytes (John et al., 2009a,b). A pathogenic isolate of N.
meningitidis, strain 89I, produces a more highly phosphorylated
LOS structure that elicits higher responses from both sides of the
TLR4 signaling branches in humanmonocytic cells. The LOS from
that particular isolate induces higher levels of MyD88-dependent
products, such as TNFα, IL-1β, and IL-12 p70 as well as TRIF-
dependent products including IFNβ and CD80 (a co-stimulatory
molecule), compared to the responses elicited by the LOS from
two other Neisseria isolates (N. gonorrhoeae), which have lower
phosphorylated states (Liu et al., 2010). Hence, the phosphory-
lation status of LOS affects both MyD88-dependent as well as
TRIF-dependent signals (Liu et al., 2010).
Bordetella is another bacterial genuswith species-speciﬁcdiffer-
ences in lipidA structure andTLR4 reactivity that canbe correlated
with infectious proﬁles. The easily cleared B. bronchiseptica highly
stimulates TLR4, and this stimulation is required for clearance of
infection. The more pathogenic species, B. pertussis and B. para-
pertussis are less reactive with TLR4, and indeed TLR4 deﬁciency
does not change susceptibility to infection (Mann et al., 2004,
2005). The structural differences between these LPS forms do not
seem to be based on phosphorylation status but rather which form
of saccharide group is present:B. bronchiseptica and B. parapertus-
sis species have smooth LPS (long-chain polysaccharide), whereas
B. pertussis have rough LPS (short-chain polysaccharide; Di Fabio
et al., 1992) and exhibits very different effects on cultured human
dendritic cells than the smooth forms (Fedele et al., 2008).
Another example of structural changes in lipid A affecting vir-
ulence of Gram-negative bacterial species is in Yersinia pestis. Y.
pestis expresses a TLR4-inhibiting, tetra-acylated form of LPS
when grown at 37˚C, the temperature of mammalian hosts. How-
ever, a TLR4-activating, hexa-acylated LPS form is expressed
when Y. pestis is grown at 26˚C, the temperature of insect hosts.
Recombinant Y. pestis that have been forced to express only hexa-
acylated LPS regardless of temperature cannot sustain a lethal
infection in mice. Lethality of infection with this recombinant
Y. pestis is restored in hosts that are deﬁcient in TLR4, CD14,
or MyD88, but not TRIF or TRAM deﬁcient mice, indicating that
MyD88-associated TLR4 outcomes are required to controlY. pestis
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infection in vivo (Montminy et al., 2006), and that the bacteria has
evolved a way to evade TLR4 signaling that allows infection in
mammalian hosts.
NATURALLY OCCURRING FORMS OF MONOPHOSPHORYL
LIPID A AND THEIR EFFECTS
Darveau and colleagues have worked extensively with structurally
deﬁned forms of lipid A isolated from various organisms, in order
to study their inherent differences in inﬂammatory signaling.
Several of the lipid As are naturally monophosphorylated. Two
such forms have been isolated from the oral bacterium Porphy-
romonas gingivalis grown indifferent hemin concentrations,which
regulate the expression of bacteria-produced phosphatases. P. gin-
givalis grown in high hemin concentrations leads primarily to the
production of antagonistic, dephosphorylated, or monophospho-
rylated, tetra-acylated lipid A forms within the Gram-negative cell
wall (Reife et al., 2006). These modiﬁcations provide the organism
with a unique evasionmechanism that prevents detection by TLR4
while also decreasing the effectiveness of cationic anti-microbial
peptides due to the neutralization of the negative charge of the
bacterial cell wall (Coats et al., 2009).
The lipid A produced by the human gut symbiant, Bacteroides
thetaiotaomicron is structurally very similar to that from P. gin-
givalis grown in low hemin concentrations. Although both these
lipid A forms are penta-acylated and monophosphorylated, they
differ in the placement of the phosphate group on the diglu-
cosamine head group. B. thetaiotaomicron LPS, has its single
phosphate on the 1-carbon, whereas the phosphate on the P.
gingivalis LPS is on the 4′-carbon. This seemingly minor struc-
tural change results in differences in the ability to stimulate NF-κB
in human TLR4/human MD2-expressing HEK-293 cells in vitro
(Coats et al., 2011). However, NF-κB signaling was used as a read-
out in these in vitro studies, which is downstream of bothMyD88-
and TRIF-dependent signaling pathways. Further differences may
be appreciated if other signaling readouts were to be examined.
Overall, the differences in lipidA structure described abovehave
marked effects on TLR4 signaling, resulting in important effects
on bacterial pathogenesis. Changes that result in decreased inﬂam-
matory responses increase the ability of the bacteria to establish
infection, thus demonstrating lipid A modiﬁcations as an under-
appreciated mechanism for microbial evasion of the immune
system. Both pathogenic (P. gingivalis) and commensal (B. thetaio-
taomicron) bacteria appear to have taken advantage of monophos-
phorylation to evade sterilizing responses. More direct assessment
is needed to determine the relative usage of the MyD88- and
TRIF-dependent pathways after TLR4 engagement when using
structurally distinct forms of lipid A, and whether or not such
usage is correlated with the potential for immediate inﬂamma-
tory damage (MyD88-associated innate response) or long-term
protective immunity (TRIF-associated adaptive immunity).
Why has the mammalian LPS recognition system not evolved
to counter this threat? One can imagine, for example, that muta-
tions in TLR4 or MD2, or both, could permit much more efﬁcient
recognition of hypophosphorylated forms of LPS, which would
lead toMyD88-dependent innate responses that conceivably could
be of tremendous beneﬁt to amammalian host in responding to P.
gingivalis or other monophosphorylated pathogens. We propose,
however, that poor activation of MyD88-signaling by monophos-
phorylated lipid A is a critically important concession to prevent
highly inﬂammatory responses from damaging host tissue, such
as oral or gut epithelium, while also tolerating the preponderance
of microbes that are beneﬁcial in terms of enhancing nutrition
and preventing colonization by truly pathogenic bacteria. Because
even monophosphorylated commensal bacteria can be dangerous
if they escape their niche in the gut or oral cavity (Teng et al., 2004;
Goldstein et al., 2006), TRIF-dependent responses that are partic-
ularly relevant to adaptive immunity may provide “insurance” in
the form of rapid responses in the event of niche escape.
DETOXIFICATION OF LIPID A BY TISSUE ALKALINE
PHOSPHATASES: INFLAMMATORY IMPLICATIONS
Because lipid A-mediated inﬂammation can lead to septic shock
and death if left unchecked, the ability to detoxify lipid A mole-
cules is critical for host survival. In the late 1990s, Poelstra et al.
showed that tissue-speciﬁc alkaline phosphatases (AP) decrease
the phosphorylation state of various lipid A molecules in vitro.
From this, they hypothesized that AP work in vivo to detox-
ify endotoxin and decrease its systemic effects (Poelstra et al.,
1997a,b). It was interesting, however, that the same group also
showed that MPLA is not completely dephosphorylated by AP
(Bentala et al., 2002). Although that study did not discuss the pos-
sible biologic implications of failing to dephosphorylate MPLA
fully, the results suggest that the monophosphorylated form of
lipid A is less of a threat in locations with high levels of com-
mensal bacteria (i.e., mucosal sites), than the di- or tri-phosphate
forms. Additionally, by failing to form the non-phosphorylated
lipid A versions of MPLA, non-signaling TLR4 antagonists that
could have served as inhibitors of TLR4 binding, and activity are
not produced.
Tissue AP belong to a family of proteins that are expressed by
most tissues, but their activities are particularly high in the intes-
tine, liver, and placenta. The intestines harbor large numbers of
Gram-negative bacteria with an abundance of lipid A. Although
intestinal alkaline phosphatase (IAP) is known to help in the
uptake of nutrients such as pyridoxal phosphate andpyridoxamine
phosphate (two forms of B6 vitamins;Waymire et al., 1995) as well
as phosphate, its ability to dephosphorylate LPS in the gastroin-
testinal tract arguably helps in the maintenance of commensal or
mutual Gram-negative bacterial species in the gut without causing
either continual stimulation or endotoxin tolerance to pathologic
Gram-negative bacteria.
Bates et al. demonstrated in a zebra ﬁsh model of vertebrate
intestine that the presence of innocuous or beneﬁcial Gram-
negative bacterial species drives the expression of IAP in a
MyD88-dependent manner. Furthermore, IAP-deﬁcient zebraﬁsh
are hypersensitive to their own microbiota (Bates et al., 2007).
Oral co-administration of IAP inhibitors and fully phosphory-
lated LPS to rats leads to increased levels of LPS in the serum
(Koyama et al., 2002). IAP-deﬁcient mice exhibit a local gut endo-
toxin tolerance, but are fully responsive to LPS systemically (Chen
et al., 2011). Although IAP deletion mutants are also more sen-
sitive to DSS-induced colitis than wild-type mice, feeding them
calf IAP abrogates this effect of the deletion (Ramasamy et al.,
2011). In humans,Crohn’s disease and ulcerative colitis are known
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to be associated with lower IAP expression (Tuin et al., 2009).
Whitehead has proposed that rosacea, a chronic inﬂammatory
condition of the face, is caused by overactive immune responses
to commensal species of the skin, and has correlated rosacea
with decreases in IAP expression (Whitehead, 2009). Interest-
ingly, dietary habits that increase IAP expression can help to
decrease ﬂairs in other inﬂammatory diseases (Blanchard and
Cousins, 2000; Tuin et al., 2006; Kaur et al., 2007). In addi-
tion, expression of the TLR4-associated co-receptor, CD14, was
shown to be co-localized with AP activity in the intestine, liver,
and kidneys (Tuin et al., 2006). Together, these studies suggest
that detoxiﬁcation of LPS by tissue AP is a natural mechanism
that helps control chronic inﬂammation in the gut. Maintenance
of monophosphorylated forms of LPS, which are detoxiﬁed but
remain immunostimulatory via TRIF-biased signaling by TLR4,
may be essential for the peaceful co-existence of the vertebrate
host with its microbiota.
CONCLUSION
The signaling of TLR4 and subsequent priming and activation of
the NLRP3 inﬂammasome provides several potential avenues to
control chronic inﬂammation, especially in localized sites such as
the intestine. Therefore, developing therapeutics that can signal
through TLR4 without the danger of inﬂammasome activation
could not only safely activate the innate immune response, but
could also open new therapeutic avenues to chronic inﬂammatory
conditions in which either IL-1β or IL-18 plays an amplifying role.
The studies discussed here emphasize the importance of control-
lingmicrobiogenic inﬂammation tomicrobiota tomaintain tissue
homeostasis, while retaining the ability to tolerate monophos-
phorylated forms of lipid A. This scenario is of utmost impor-
tance in the intestine. Linking these studies with the control of
NLRP3 inﬂammasome will increase our understanding of inﬂam-
matory disease progression and help in determining potential for
therapeutic interventions.
REFERENCES
Akazawa, T., Masuda, H., Saeki, Y., Mat-
sumoto, M., Takeda, K., Tsujimura,
K., Kuzushima, K., Takahashi, T.,
Azuma, I., Akira, S., Toyoshima,
K., and Seya, T. (2004). Adjuvant-
mediated tumor regression and
tumor-speciﬁc cytotoxic response
are impaired in MyD88-deﬁcient
mice. Cancer Res. 64, 757–764.
Allen, I. C., TeKippe, E. M., Woodford,
R. M., Uronis, J. M., Holl, E. K.,
Rogers, A. B., Herfarth, H. H., Jobin,
C., andTing, J. P. (2010). TheNLRP3
inﬂammasome functions as a nega-
tive regulator of tumorigenesis dur-
ing colitis-associated cancer. J. Exp.
Med. 207, 1045–1056.
Arend, W. P., Palmer, G., and Gabay, C.
(2008). IL-1, IL-18, and IL-33 fami-
lies of cytokines. Immunol. Rev. 223,
20–38.
Arslan, F., de Kleijn, D. P., and Pas-
terkamp, G. (2011). Innate immune
signaling in cardiac ischemia. Nat.
Rev. Cardiol. 8, 292–300.
Baldrick, P., Richardson, D., Elliott, G.,
and Wheeler, A. W. (2002). Safety
evaluation of monophosphoryl lipid
A (MPL): an immunostimulatory
adjuvant. Regul. Toxicol. Pharmacol.
35, 398–413.
Bates, J. M., Akerlund, J., Mittge, E.,
and Guillemin, K. (2007). Intesti-
nal alkaline phosphatase detoxi-
ﬁes lipopolysaccharide and pre-
vents inﬂammation in zebraﬁsh in
response to the gut microbiota. Cell
Host Microbe 2, 371–382.
Bauernfeind, F. G., Horvath, G., Stutz,
A., Alnemri, E. S., MacDonald, K.,
Speert, D., Fernandes-Alnemri, T.,
Wu, J., Monks, B. G., Fitzgerald, K.
A., Hornung,V., and Latz, E. (2009).
Cutting edge: NF-kappaB activat-
ing pattern recognition and cytokine
receptors license NLRP3 inﬂam-
masome activation by regulating
NLRP3 expression. J. Immunol. 183,
787–791.
Bentala, H., Verweij, W. R., Huizinga-
van der Vlag, A., van Loenen-
Weemaes, A. M., Meijer, D. K.,
and Poelstra, K. (2002). Removal of
phosphate from lipid A as a strategy
todetoxify lipopolysaccharide.Shock
18, 561–566.
Bettini, M., and Vignali, D. A. (2011).
T cell-driven initiation and propaga-
tion of autoimmune diabetes. Curr.
Opin. Immunol. 23, 754–760.
Blanchard, R. K., and Cousins, R. J.
(2000). Regulation of intestinal gene
expression by dietary zinc: induction
of uroguanylin mRNA by zinc deﬁ-
ciency. J. Nutr. 130, 1393S–1398S.
Blanco, P., Palucka, A. K., Pascual, V.,
and Banchereau, J. (2008). Den-
dritic cells and cytokines in human
inﬂammatory and autoimmune dis-
eases. Cytokine Growth Factor Rev.
19, 41–52.
Carpenter, S., and O’Neill, L. A.
(2009). Recent insights into the
structure of Toll-like receptors and
post-translational modiﬁcations of
their associated signalling proteins.
Biochem. J. 422, 1–10.
Cekic, C., Casella, C. R., Eaves, C.
A., Matsuzawa, A., Ichijo, H., and
Mitchell, T. C. (2009). Selective acti-
vation of the p38 MAPK path-
way by synthetic monophosphoryl
lipid A. J. Biol. Chem. 284, 31982–
31991.
Cekic, C., Casella, C. R., Sag, D.,
Antignano, F., Kolb, J., Suttles, J.,
Hughes, M. R., Krystal, G., and
Mitchell, T. C. (2011). MyD88-
dependent SHIP1 regulates proin-
ﬂammatory signaling pathways in
dendritic cells after monophospho-
ryl lipid A stimulation of TLR4. J.
Immunol. 186, 3858–3865.
Chen, K. T., Malo, M. S., Beasley-
Topliffe, L. K., Poelstra, K., Mil-
lan, J. L., Mostafa, G., Alam, S.
N., Ramasamy, S., Warren, H. S.,
Hohmann, E. L., and Hodin, R. A.
(2011). A role for intestinal alkaline
phosphatase in the maintenance of
local gut immunity. Dig. Dis. Sci. 56,
1020–1027.
Coats, S. R.,Berezow,A. B.,To,T. T., Jain,
S., Bainbridge, B. W., Banani, K. P.,
and Darveau, R. P. (2011). The lipid
A phosphate position determines
differential host Toll-like receptor 4
responses to phylogenetically related
symbiotic and pathogenic bacteria.
Infect. Immun. 79, 203–210.
Coats, S. R., Reife, R. A., Bainbridge,
B. W., Pham, T. T., and Darveau,
R. P. (2003). Porphyromonas gingi-
valis lipopolysaccharide antagonizes
Escherichia coli lipopolysaccharide
at toll-like receptor 4 in human
endothelial cells. Infect. Immun. 71,
6799–6807.
Coats, S. R., To, T. T., Jain, S., Braham, P.
H., and Darveau, R. P. (2009). Por-
phyromonas gingivalis resistance to
polymyxin B is determined by the
lipid A 4’-phosphatase, PGN_0524.
Int. J. Oral Sci. 1, 126–135.
Coussens, L. M., and Werb, Z. (2002).
Inﬂammation and cancer. Nature
420, 860–867.
Davalos, D., and Akassoglou, K. (2012).
Fibrinogen as a key regulator of
inﬂammation in disease. Semin.
Immunopathol. 34, 43–62.
Delogu, L. G., Deidda, S., Delitala, G.,
and Manetti, R. (2011). Infectious
diseases and autoimmunity. J. Infect.
Dev. Ctries. 5, 679–687.
Di Fabio, J. L., Caroff, M., Karibian,
D., Richards, J. C., and Perry, M.
B. (1992). Characterization of the
common antigenic lipopolysaccha-
ride O-chains produced by Borde-
tella bronchiseptica and Bordetella
parapertussis. FEMS Microbiol. Lett.
76, 275–281.
Didierlaurent, A. M., Morel, S., Lock-
man, L., Giannini, S. L., Bisteau,
M., Carlsen,H., Kielland,A.,Vosters,
O., Vanderheyde, N., Schiavetti, F.,
Larocque, D., Van, M. M., and
Garcon, N. (2009). AS04, an alu-
minum salt- and TLR4 agonist-
based adjuvant system, induces a
transient localized innate immune
response leading to enhanced adap-
tive immunity. J. Immunol. 183,
6186–6197.
Duewell, P., Kono, H., Rayner, K. J.,
Sirois, C. M., Vladimer, G., Bauern-
feind, F. G., Abela, G. S., Franchi,
L., Nunez, G., Schnurr, M., Espe-
vik, T., Lien, E., Fitzgerald, K. A.,
Rock, K. L., Moore, K. J., Wright,
S. D., Hornung, V., and Latz, E.
(2010). NLRP3 inﬂammasomes are
required for atherogenesis and acti-
vated by cholesterol crystals. Nature
464, 1357–1361.
Dunne, A. (2011). Inﬂammasome acti-
vation: from inﬂammatory disease
to infection. Biochem. Soc. Trans. 39,
669–673.
Embry,C.A., Franchi, L.,Nunez,G., and
Mitchell, T. C. (2011). Mechanism
of impaired NLRP3 inﬂammasome
priming by monophosphoryl lipid
A. Sci. Signal. 4, ra28.
Fedele, G., Nasso, M., Spensieri, F.,
Palazzo, R., Frasca, L., Watan-
abe, M., and Ausiello, C. M.
(2008). Lipopolysaccharides from
Bordetella pertussis and Bordetella
parapertussis differently modulate
human dendritic cell functions
resulting in divergent prevalence of
Frontiers in Immunology | Inﬂammation June 2012 | Volume 3 | Article 154 | 6
Chilton et al. Lipid A structure changes and inﬂammatory signaling
Th17-polarized responses. J.
Immunol. 181, 208–216.
Foell, D., Wittkowski, H., and Roth,
J. (2007). Mechanisms of disease:
a “DAMP” view of inﬂammatory
arthritis. Nat. Clin. Pract. Rheuma-
tol. 3, 382–390.
Garrett, W. S., Gallini, C. A., Yat-
sunenko, T., Michaud, M., DuBois,
A., Delaney, M. L., Punit, S., Karls-
son, M., Bry, L., Glickman, J. N.,
Gordon, J. I., Onderdonk, A. B., and
Glimcher, L. H. (2010). Enterobac-
teriaceae act in concert with the gut
microbiota to induce spontaneous
and maternally transmitted colitis.
Cell Host Microbe 8, 292–300.
Goldstein, E. J., Citron, D. M., Vaidya,
S. A., Warren, Y. A., Tyrrell, K.
L., Vreni, M. C., and Fernandez,
H. (2006). In vitro activity of
11 antibiotics against 74 anaer-
obes isolated from pediatric intra-
abdominal infections. Anaerobe 12,
63–66.
Grivennikov, S. I., Greten, F. R., and
Karin,M. (2010). Immunity, inﬂam-
mation, and cancer. Cell 140, 883–
899.
Hirota, S. A., Ng, J., Lueng, A., Khajah,
M., Parhar, K., Li, Y., Lam,V., Poten-
tier, M. S., Ng, K., Bawa, M., McCaf-
ferty, D. M., Rioux, K. P., Ghosh, S.,
Xavier, R. J., Colgan, S. P., Tschopp,
J., Muruve, D., Macdonald, J. A., and
Beck, P. L. (2011). NLRP3 inﬂam-
masome plays a key role in the
regulation of intestinal homeostasis.
Inﬂamm. Bowel Dis. 17, 1359–1372.
Janeway, C. A. Jr., and Medzhitov, R.
(2002). Innate immune recognition.
Annu. Rev. Immunol. 20, 197–216.
John, C. M., Liu, M., and Jarvis, G.
A. (2009a). Natural phosphoryl and
acyl variants of lipidA fromNeisseria
meningitidis strain 89I differentially
induce tumor necrosis factor-alpha
in human monocytes. J. Biol. Chem.
284, 21515–21525.
John, C. M., Liu, M., and Jarvis, G.
A. (2009b). Proﬁles of structural
heterogeneity in native lipooligosac-
charides of Neisseria and cytokine
induction. J. Lipid Res. 50,
424–438.
Kaur, J., Madan, S., Hamid, A., Singla,
A., andMahmood,A. (2007). Intesti-
nal alkaline phosphatase secretion
in oil-fed rats. Dig. Dis. Sci. 52,
665–670.
Kawai, T., and Akira, S. (2009). The
roles of TLRs, RLRs and NLRs in
pathogen recognition. Int. Immunol.
21, 317–337.
Kennedy, M. N., Mullen, G. E., Leifer,
C. A., Lee, C.,Mazzoni, A., Dileepan,
K. N., and Segal, D. M. (2004).
A complex of soluble MD-2 and
lipopolysaccharide serves as an acti-
vating ligand for Toll-like receptor 4.
J. Biol. Chem. 279, 34698–34704.
Koike, R., Kubota, T., Hara, Y., Ito, S.,
Suzuki, K., Yanagisawa, K., Uchi-
bori, K., and Miyasaka, N. (2007).
A case of Muckle-Wells syndrome
caused by a novel H312P muta-
tion in NALP3 (cryopyrin). Mod.
Rheumatol. 17, 496–499.
Koyama, I., Matsunaga, T., Harada, T.,
Hokari, S., and Komoda, T. (2002).
Alkaline phosphatases reduce toxi-
city of lipopolysaccharides in vivo
and in vitro through dephos-
phorylation. Clin. Biochem. 35,
455–461.
Kubota, T., and Koike, R. (2010).
Cryopyrin-associated periodic
syndromes: background and ther-
apeutics. Mod. Rheumatol. 20,
213–221.
Liu, M., John, C. M., and Jarvis, G.
A. (2010). Phosphoryl moieties of
lipid A from Neisseria meningitidis
and N. gonorrhoeae lipooligosac-
charides play an important role
in activation of both MyD88- and
TRIF-dependent TLR4-MD-2 sig-
naling pathways. J. Immunol. 185,
6974–6984.
Madonna, G. S., Peterson, J. E., Ribi, E.
E., and Vogel, S. N. (1986). Early-
phase endotoxin tolerance: induc-
tion by a detoxiﬁed lipid A deriva-
tive,monophosphoryl lipidA. Infect.
Immun. 52, 6–11.
Mann, P. B., Elder, K. D., Kennett, M.
J., and Harvill, E. T. (2004). Toll-like
receptor 4-dependent early elicited
tumor necrosis factor alpha expres-
sion is critical for innate host defense
against Bordetella bronchiseptica.
Infect. Immun. 72, 6650–6658.
Mann, P. B., Wolfe, D., Latz, E.,
Golenbock, D., Preston, A., and
Harvill, E. T. (2005). Comparative
toll-like receptor 4-mediated innate
host defense to Bordetella infection.
Infect. Immun. 73, 8144–8152.
Martinon, F., Burns, K., and Tschopp, J.
(2002). The inﬂammasome: a mole-
cular platform triggering activation
of inﬂammatory caspases and pro-
cessing of proIL-beta. Mol. Cell 10,
417–426.
Martinon, F., Petrilli, V., Mayor, A., Tar-
divel, A., and Tschopp, J. (2006).
Gout-associated uric acid crystals
activate the NALP3 inﬂammasome.
Nature 440, 237–241.
Mata-Haro, V., Cekic, C., Martin,
M., Chilton, P. M., Casella, C.
R., and Mitchell, T. C. (2007).
The vaccine adjuvant monophos-
phoryl lipid A as a TRIF-biased
agonist of TLR4. Science 316,
1628–1632.
McDermott, M. F., and Aksentijevich, I.
(2002). The autoinﬂammatory syn-
dromes. Curr. Opin. Allergy Clin.
Immunol. 2, 511–516.
Montminy, S. W., Khan, N., McGrath,
S., Walkowicz, M. J., Sharp, F., Con-
lon, J. E., Fukase, K., Kusumoto,
S., Sweet, C., Miyake, K., Akira, S.,
Cotter, R. J., Goguen, J. D., and
Lien, E. (2006). Virulence factors of
Yersinia pestis are overcome by a
strong lipopolysaccharide response.
Nat. Immunol. 7, 1066–1073.
Murray, T. S., and Shapiro, E. D. (2010).
Lyme disease. Clin. Lab. Med. 30,
311–328.
Niemi, K., Teirila, L., Lappalainen, J.,
Rajamaki, K., Baumann, M. H.,
Oorni, K., Wolff, H., Kovanen, P.
T., Matikainen, S., and Eklund, K.
K. (2011). Serum amyloid A acti-
vates the NLRP3 inﬂammasome via
P2×7 receptor and a cathepsin B-
sensitive pathway. J. Immunol. 186,
6119–6128.
Okemoto, K., Kawasaki, K., Hanada,
K., Miura, M., and Nishijima,
M. (2006). A potent adjuvant
monophosphoryl lipid A triggers
various immune responses, but not
secretion of IL-1beta or activa-
tion of caspase-1. J. Immunol. 176,
1203–1208.
Osawa, R., Williams, K. L., and
Singh, N. (2011). The inﬂamma-
some regulatory pathway and infec-
tions: role in pathophysiology and
clinical implications. J. Infect. 62,
119–129.
Park, B. S., Song, D. H., Kim, H.
M., Choi, B. S., Lee, H., and Lee,
J. O. (2009). The structural basis
of lipopolysaccharide recognition by
the TLR4-MD-2 complex. Nature
458, 1191–1195.
Pelegrin, P., Barroso-Gutierrez, C., and
Surprenant, A. (2008). P2×7 recep-
tor differentially couples to dis-
tinct release pathways for IL-1beta
in mouse macrophage. J. Immunol.
180, 7147–7157.
Poelstra, K., Bakker, W. W., Klok, P.
A., Hardonk, M. J., and Meijer,
D. K. (1997a). A physiologic func-
tion for alkaline phosphatase: endo-
toxin detoxiﬁcation. Lab. Invest. 76,
319–327.
Poelstra, K., Bakker, W. W., Klok, P. A.,
Kamps, J. A., Hardonk, M. J., and
Meijer,D.K. (1997b).Dephosphory-
lation of endotoxin by alkaline phos-
phatase in vivo. Am. J. Pathol. 151,
1163–1169.
Poltorak, A., Smirnova, I., He, X., Liu,
M. Y., Van, H. C., McNally, O., Bird-
well, D., Alejos, E., Silva, M., Du, X.,
Thompson, P., Chan, E. K., Ledesma,
J., Roe, B., Clifton, S., Vogel, S. N.,
and Beutler, B. (1998). Genetic and
physical mapping of the Lps locus:
identiﬁcation of the toll-4 receptor
as a candidate gene in the criti-
cal region. Blood Cells Mol. Dis. 24,
340–355.
Raetz, C. R., and Whitﬁeld, C.
(2002). Lipopolysaccharide endo-
toxins. Annu. Rev. Biochem. 71,
635–700.
Ramasamy, S., Nguyen, D. D., Eston,
M. A., Alam, S. N., Moss, A. K.,
Ebrahimi, F., Biswas, B., Mostafa, G.,
Chen, K. T., Kaliannan, K., Yam-
mine, H., Narisawa, S., Millan, J.
L., Warren, H. S., Hohmann, E.
L., Mizoguchi, E., Reinecker, H. C.,
Bhan, A. K., Snapper, S. B., Malo, M.
S., and Hodin, R. A. (2011). Intesti-
nal alkaline phosphatase has ben-
eﬁcial effects in mouse models of
chronic colitis. Inﬂamm. Bowel. Dis.
17, 532–542.
Reife, R. A., Coats, S. R., Al-Qutub, M.,
Dixon,D.M.,Braham,P.A.,Billharz,
R. J., Howald, W. N., and Darveau,
R. P. (2006). Porphyromonas
gingivalis lipopolysaccharide
lipid A heterogeneity: differential
activities of tetra- and penta-
acylated lipid A structures on
E-selectin expression and TLR4
recognition. Cell. Microbiol. 8,
857–868.
Ribi, E. (1984). Beneﬁcial modiﬁcation
of the endotoxin molecule. J. Biol.
Response Mod. 3, 1–9.
Roach, J. C., Glusman, G., Rowen,
L., Kaur, A., Purcell, M. K.,
Smith, K. D., Hood, L. E., and
Aderem, A. (2005). The evolution
of vertebrate Toll-like receptors.
Proc. Natl. Acad. Sci. U.S.A. 102,
9577–9582.
Rock, K. L., Lai, J. J., and Kono, H.
(2011). Innate and adaptive immune
responses to cell death. Immunol.
Rev. 243, 191–205.
Schilling, D., Thomas, K., Nixdorff, K.,
Vogel,S.N., andFenton,M. J. (2002).
Toll-like receptor 4 and Toll-IL-1
receptor domain-containing adapter
protein (TIRAP)/myeloid differenti-
ation protein 88 adapter-like (Mal)
contribute to maximal IL-6 expres-
sion in macrophages. J. Immunol.
169, 5874–5880.
Schroder, K., and Tschopp, J. (2010).
The inﬂammasomes. Cell 140,
821–832.
Sikora, K. A., and Grom, A. A. (2011).
Update on the pathogenesis and
treatment of systemic idiopathic
arthritis. Curr. Opin. Pediatr. 23,
640–646.
Starczynowski, D. T., and Karsan, A.
(2010). Innate immune signaling
in the myelodysplastic syndromes.
www.frontiersin.org June 2012 | Volume 3 | Article 154 | 7
Chilton et al. Lipid A structure changes and inﬂammatory signaling
Hematol. Oncol. Clin. North Am. 24,
343–359.
Stover, A. G., Da Silva, C. J., Evans, J.
T., Cluff, C. W., Elliott, M. W., Jef-
fery,E.W., Johnson,D.A.,Lacy,M. J.,
Baldridge, J. R., Probst, P., Ulevitch,
R. J., Persing, D. H., and Hershberg,
R.M. (2004). Structure-activity rela-
tionship of synthetic toll-like recep-
tor 4 agonists. J. Biol. Chem. 279,
4440–4449.
Stutz, A., Golenbock, D. T., and
Latz, E. (2009). Inﬂammasomes: too
big to miss. J. Clin. Invest. 119,
3502–3511.
Suerbaum, S., and Michetti, P. (2002).
Helicobacter pylori infection. N.
Engl. J. Med. 347, 1175–1186.
Teng, L. J., Hsueh, P. R., Huang, Y. H.,
and Tsai, J. C. (2004). Identiﬁcation
of bacteroides thetaiotaomicron on
the basis of an unexpected speciﬁc
amplicon of universal 16S riboso-
mal DNA PCR. J. Clin. Microbiol. 42,
1727–1730.
Thompson, B. S., Chilton, P. M., Ward,
J. R., Evans, J. T., and Mitchell,
T. C. (2005). The low-toxicity ver-
sions of LPS, MPL adjuvant and
RC529, are efﬁcient adjuvants for
CD4+ T cells. J. Leukoc. Biol. 78,
1273–1280.
Tuin, A., Huizinga-van der Vlag,
A., van Loenen-Weemaes, A. M.,
Meijer, D. K., and Poelstra, K.
(2006). On the role and fate
of LPS-dephosphorylating activity
in the rat liver. Am. J. Phys-
iol. Gastrointest. Liver Physiol. 290,
G377–G385.
Tuin, A., Poelstra, K., de Jager-Krikken,
A., Bok, L., Raaben, W., Velders,
M. P., and Dijkstra, G. (2009).
Role of alkaline phosphatase in
colitis in man and rats. Gut 58,
379–387.
Waymire, K. G., Mahuren, J. D., Jaje,
J. M., Guilarte, T. R., Coburn, S.
P., and MacGregor, G. R. (1995).
Mice lacking tissue non-speciﬁc
alkaline phosphatase die from
seizures due to defective metabolism
of vitamin B-6. Nat. Genet. 11,
45–51.
Whitehead, J. (2009). Intestinal alka-
line phosphatase: the molecular link
between rosacea and gastrointesti-
nal disease? Med. Hypotheses 73,
1019–1022.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 19 March 2012; paper pend-
ing published: 03 April 2012; accepted:
25 May 2012; published online: 13 June
2012.
Citation: Chilton PM, Embry CA and
Mitchell TC (2012) Effects of differ-
ences in lipid A structure on TLR4 pro-
inﬂammatory signaling and inﬂamma-
some activation. Front. Immun. 3:154.
doi: 10.3389/ﬁmmu.2012.00154
This article was submitted to Frontiers in
Inﬂammation, a specialty of Frontiers in
Immunology.
Copyright © 2012 Chilton, Embry
and Mitchell. This is an open-access
article distributed under the terms
of the Creative Commons Attribution
Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
Frontiers in Immunology | Inﬂammation June 2012 | Volume 3 | Article 154 | 8
